FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Flatt

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Disorders

Co-author Network

Publications

TOP 3
Christine M A Martin; Nigel Irwin; Peter R Flatt; Victor A Gault
A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores.
Vikas K Bhat; Peter R Flatt; Barry D Kerr; Victor A Gault
A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
V K Bhat; Peter R Flatt; B D Kerr; S Vasu; Victor A Gault
A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Flatt (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Christine M A Martin; Nigel Irwin; Peter R Flatt; Victor A Gault
A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores.
Biochimica et biophysica acta 2013;1830(6):3407-13.
2013: Vikas K Bhat; Peter R Flatt; Barry D Kerr; Victor A Gault
A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
Biochemical pharmacology 2013;85(11):1655-62.
2013: V K Bhat; Peter R Flatt; B D Kerr; S Vasu; Victor A Gault
A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Diabetologia 2013;56(6):1417-24.
2013: Nigel Irwin; I A Montgomery; Peter R Flatt
Comparison of the metabolic effects of sustained CCK1 receptor activation alone and in combination with upregulated leptin signalling in high-fat-fed mice.
Diabetologia 2013;56(6):1425-35.
2013: W D Porter; Christian Hölscher; Peter R Flatt; Victor A Gault
Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice.
International journal of obesity (2005) 2013;37(5):678-84.
2013: Rachael Lennox; David W Porter; Peter R Flatt; Victor A Gault
(Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and β-cell function in high-fat-fed mice.
ChemMedChem 2013;8(4):595-602.
2013: O O Ojo; J Michael Conlon; Peter R Flatt; Yasser H A Abdel-Wahab
Frog skin peptides (tigerinin-1R, magainin-AM1, -AM2, CPF-AM1, and PGla-AM1) stimulate secretion of glucagon-like peptide 1 (GLP-1) by GLUTag cells.
Biochemical and biophysical research communications 2013;431(1):14-8.
2013: Dinesh Srinivasan; Yasser H A Abdel-Wahab; Peter R Flatt; Milena Mechkarska; J Michael Conlon
Caerulein precursor fragment (CPF) peptides from the skin secretions of Xenopus laevis and Silurana epitropicalis are potent insulin-releasing agents.
Biochimie 2013;95(2):429-35.
2013: Nigel Irwin; R Charlotte Moffett; Ian A Montgomery; Peter R Flatt
Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
Biochemical pharmacology 2013;85(1):81-91.
2013: Nigel Irwin; Finbarr P M O'Harte; Pamela Frizelle; Peter R Flatt
Metabolic effects of activation of CCK receptor signaling pathways by twice-daily administration of the enzyme-resistant CCK-8 analog, (pGlu-Gln)-CCK-8, in normal mice.
The Journal of endocrinology 2013;216(1):53-9.
2012: Nigel Irwin; R C Moffett; I A Montgomery; F P M O'Harte; P Frizelle; Peter R Flatt
Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes.
Diabetologia 2012;55(10):2747-58.
2012: Hong Guo-Parke; Muhajir Hamid; Catriona Kelly; Neville H McClenaghan; Jane T McCluskey; Peter R Flatt
Configuration of electrofusion-derived human insulin-secreting cell line as pseudoislets enhances functionality and therapeutic utility.
The Journal of endocrinology 2012;214(3):257-65.
2012: Christine M A Martin; Stephen McClean; Peter R Flatt; Victor A Gault; Nigel Irwin
Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25.
Biochemical pharmacology 2012;84(3):312-9.
2012: Nigel Irwin; Ian A Montgomery; Peter R Flatt
Evaluation of the long-term effects of gastric inhibitory polypeptide-ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed mice.
The British journal of nutrition 2012;108(1):46-56.
2012: David Porter; Christian Hölscher; Emilie Faivre; Peter R Flatt; Victor A Gault
Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice.
Peptides 2012;35(1):1-8.
2011: O O Ojo; Yasser H A Abdel-Wahab; Peter R Flatt; M Mechkarska; J M Conlon
Tigerinin-1R: a potent, non-toxic insulin-releasing peptide isolated from the skin of the Asian frog, Hoplobatrachus rugulosus.
Diabetes, obesity & metabolism 2011;13(12):1114-22.
2011: Nigel Irwin; Jacqueline M E Francis; Peter R Flatt
Insulin modulates glucose-dependent insulinotropic polypeptide (GIP) secretion from enteroendocrine K cells in rats.
Biological chemistry 2011;392(10):909-18.
2011: Z J Franklin; B McDonnell; I A Montgomery; Peter R Flatt; Nigel Irwin
Dual modulation of GIP and glucagon action by the low molecular weight compound 4-hydroxybenzoic acid 2-bromobenzylidene hydrazide.
Diabetes, obesity & metabolism 2011;13(8):742-9.
2011: Victor A Gault; Patrick Harriott; Barry D Kerr; Peter R Flatt
Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Clinical science (London, England : 1979) 2011;121(3):107-17.
2011: M B Paget; H E Murray; Clifford J Bailey; Peter R Flatt; Richard Downing
Rotational co-culture of clonal β-cells with endothelial cells: effect of PPAR-γ agonism in vitro on insulin and VEGF secretion.
Diabetes, obesity & metabolism 2011;13(7):662-8.
2011: Jane T McCluskey; Ramon Gomis; Hong Guo-Parke; Muhajir Hamid; Neville H McClenaghan; Peter R Flatt
Development and functional characterization of insulin-releasing human pancreatic beta cell lines produced by electrofusion.
The Journal of biological chemistry 2011;286(25):21982-92.
2011: Osama K Zahid; Milena Mechkarska; Opeolu Ojo; Yasser H A Abdel-Wahab; Peter R Flatt; Mohammed A Meetani; J Michael Conlon
Caerulein-and xenopsin-related peptides with insulin-releasing activities from skin secretions of the clawed frogs, Xenopus borealis and Xenopus amieti (Pipidae).
General and comparative endocrinology 2011;172(2):314-20.
2011: Nigel Irwin; J M McKinney; Clifford J Bailey; Neville H McClenaghan; Peter R Flatt
Acute and long-term effects of peroxisome proliferator-activated receptor-γ activation on the function and insulin secretory responsiveness of clonal beta-cells.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2011;43(4):244-9.
2011: Victor A Gault; David W Porter; Nigel Irwin; Peter R Flatt
Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice.
The Journal of endocrinology 2011;208(3):265-71.
2011: Milena Mechkarska; Opeolu Ojo; Mohammed A Meetani; Laurent Coquet; THIERRY JOUENNE; Yasser H A Abdel-Wahab; Peter R Flatt; Jay D King; J Michael Conlon
Peptidomic analysis of skin secretions from the bullfrog Lithobates catesbeianus (Ranidae) identifies multiple peptides with potent insulin-releasing activity.
Peptides 2011;32(2):203-8.
2011: Barry D Kerr; Anneliese J S Flatt; Peter R Flatt; Victor A Gault
Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide.
Biochemical and biophysical research communications 2011;404(3):870-6.
2011: David W Porter; Nigel Irwin; Peter R Flatt; Christian Hölscher; Victor A Gault
Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice.
European journal of pharmacology 2011;650(2-3):688-93.
2010: Joan M McKiney; Nigel Irwin; Peter R Flatt; Clifford J Bailey; Neville H McClenaghan
Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal β-cells.
Biological chemistry 2010;391(12):1451-9.
2010: Barry D Kerr; Peter R Flatt; Victor A Gault
(D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions.
Biochemical pharmacology 2010;80(11):1727-35.
2010: D W Porter; B D Kerr; Peter R Flatt; C Holscher; Victor A Gault
Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance.
Diabetes, obesity & metabolism 2010;12(10):891-9.
2010: Catriona Kelly; Hong Guo Parke; Jane T McCluskey; Peter R Flatt; Neville H McClenaghan
The role of glucagon- and somatostatin-secreting cells in the regulation of insulin release and beta-cell function in heterotypic pseudoislets.
Diabetes/metabolism research and reviews 2010;26(7):525-33.
2010: Ashley I Taylor; Nigel Irwin; Aine M McKillop; Steven Patterson; Peter R Flatt; Victor A Gault
Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety.
The Journal of endocrinology 2010;207(1):87-93.
2010: Nigel Irwin; Victor Gault; Peter R Flatt
Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?
Expert opinion on investigational drugs 2010;19(9):1039-48.
2010: I A Montgomery; Nigel Irwin; Peter R Flatt
Active immunization against (Pro(3))GIP improves metabolic status in high-fat-fed mice.
Diabetes, obesity & metabolism 2010;12(9):744-51.
2010: Catriona Kelly; Peter R Flatt; Neville H McClenaghan
Cell-to-cell communication and cellular environment alter the somatostatin status of delta cells.
Biochemical and biophysical research communications 2010;399(2):162-6.
2010: Y H A Abdel-Wahab; Steven Patterson; Peter R Flatt; J Michael Conlon
Brevinin-2-related peptide and its [D4K] analogue stimulate insulin release in vitro and improve glucose tolerance in mice fed a high fat diet.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2010;42(9):652-6.
2010: Barry D Kerr; Peter R Flatt; Victor A Gault
Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1.
Biochemical pharmacology 2010;80(3):396-401.
2010: Victor A Gault; W D Porter; Peter R Flatt; Christian Hölscher
Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet.
International journal of obesity (2005) 2010;34(8):1341-4.
2010: Nigel Irwin; Peter R Flatt; Steven Patterson; Brian D Green
Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.
European journal of pharmacology 2010;628(1-3):268-73.
2009: Aine M McKillop; Nicola A Duffy; John Lindsay; Brian D Green; Steven Patterson; Finbarr P M O'Harte; Patrick M Bell; Peter R Flatt
Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
European journal of endocrinology / European Federation of Endocrine Societies 2009;161(6):877-85.
2009: A I Taylor; Norma Frizzell; Aine M McKillop; Peter R Flatt; Victor A Gault
Effect of RU486 on hepatic and adipocyte gene expression improves diabetes control in obesity-type 2 diabetes.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2009;41(12):899-904.
2009: Barry D Kerr; Nigel Irwin; Finbarr P M O'Harte; Clifford J Bailey; Peter R Flatt; Victor A Gault
Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.
Biochemical pharmacology 2009;78(8):1008-16.
2009: Nigel Irwin; Peter R Flatt
Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications.
Diabetologia 2009;52(9):1724-31.
2009: Nigel Irwin; Peter R Flatt
Therapeutic potential for GIP receptor agonists and antagonists.
Best practice & research. Clinical endocrinology & metabolism 2009;23(4):499-512.
2009: Nigel Irwin; Paula L McClean; Kerry Hunter; Peter R Flatt
Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice.
Diabetes, obesity & metabolism 2009;11(6):603-10.
2009: J Michael Conlon; Yasser H A Abdel-Wahab; Peter R Flatt; Jérôme Leprince; Hubert Vaudry; THIERRY JOUENNE; Eric Condamine
A glycine-leucine-rich peptide structurally related to the plasticins from skin secretions of the frog Leptodactylus laticeps (Leptodactylidae).
Peptides 2009;30(5):888-92.
2009: Nigel Irwin; Kerry Hunter; Norma Frizzell; Peter R Flatt
Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice.
Regulatory peptides 2009;153(1-3):70-6.
2009: Peter R Flatt; C J Bailey; Brian D Green
Recent advances in antidiabetic drug therapies targeting the enteroinsular axis.
Current drug metabolism 2009;10(2):125-37.
2009: Barry D Kerr; Nigel Irwin; Peter R Flatt; Victor A Gault
Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intolerance.
Peptides 2009;30(2):219-25.
2009: Neville H McClenaghan; Siobhan M Scullion; Brian Mion; Chandralal Hewage; J Paul G Malthouse; Peter R Flatt; Philip Newsholme; Lorraine Brennan
Prolonged L-alanine exposure induces changes in metabolism, Ca(2+) handling and desensitization of insulin secretion in clonal pancreatic beta-cells.
Clinical science (London, England : 1979) 2009;116(4):341-51.
2008: Yasser H A Abdel-Wahab; Gavin J Power; Peter R Flatt; Douglas C Woodhams; Louise A Rollins-Smith; J Michael Conlon
A peptide of the phylloseptin family from the skin of the frog Hylomantis lemur (Phyllomedusinae) with potent in vitro and in vivo insulin-releasing activity.
Peptides 2008;29(12):2136-43.
2008: J Michael Conlon; Gavin J Power; Yasser H A Abdel-Wahab; Peter R Flatt; Hu Jiansheng; Laurent Coquet; Jérôme Leprince; THIERRY JOUENNE; Hubert Vaudry
A potent, non-toxic insulin-releasing peptide isolated from an extract of the skin of the Asian frog, Hylarana guntheri (Anura:Ranidae).
Regulatory peptides 2008;151(1-3):153-9.
2008: Paula L McClean; Nigel Irwin; Kerry Hunter; Victor A Gault; Peter R Flatt
(Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy.
British journal of pharmacology 2008;155(5):690-701.
2008: Peter R Flatt
Dorothy Hodgkin Lecture 2008. Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes?
Diabetic medicine : a journal of the British Diabetic Association 2008;25(7):759-64.
2008: Victor A Gault; Barry D Kerr; Nigel Irwin; Peter R Flatt
C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes.
Biochemical pharmacology 2008;75(12):2325-33.
2008: Nigel Irwin; Kerry Hunter; Peter R Flatt
Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice.
Peptides 2008;29(6):1036-41.
2008: Liu Hui-Kang; Jane T McCluskey; Neville H McClenghan; Peter R Flatt
Iterative exposure of clonal BRIN-BD11 cells to ninhydrin enables selection of robust toxin-resistant cells but with decreased gene expression of insulin secretory function.
Pancreas 2008;36(3):294-301.
2008: P L McClean; Victor A Gault; Nigel Irwin; Jane T McCluskey; Peter R Flatt
Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIP.
Diabetes, obesity & metabolism 2008;10(4):336-42.
2008: Ashley Taylor; Nigel Irwin; Aine M McKillop; Peter R Flatt; Victor A Gault
Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
Biological chemistry 2008;389(4):441-5.
2008: Nigel Irwin; Kerry Hunter; Norma Frizzell; Peter R Flatt
Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice.
European journal of pharmacology 2008;581(1-2):226-33.
2008: Yasser H A Abdel-Wahab; Gavin J Power; Ming T Ng; Peter R Flatt; J Michael Conlon
Insulin-releasing properties of the frog skin peptide pseudin-2 and its [Lys18]-substituted analogue.
Biological chemistry 2008;389(2):143-8.
2008: Roslyn S Cassidy; Nigel Irwin; Peter R Flatt
Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets.
Biological chemistry 2008;389(2):189-93.
2008: Peter R Flatt; Clifford J Bailey; Brian D Green
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
Frontiers in bioscience : a journal and virtual library 2008;13():3648-60.
2008: Aine M McKillop; Nicola A Duffy; John Lindsay; Finbarr P M O'Harte; Patrick M Bell; Peter R Flatt
Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects.
Diabetes research and clinical practice 2008;79(1):79-85.
2007: Brian D Green; Peter R Flatt
Incretin hormone mimetics and analogues in diabetes therapeutics.
Best practice & research. Clinical endocrinology & metabolism 2007;21(4):497-516.
2007: Paula L McClean; Nigel Irwin; Roslyn S Cassidy; Jens J Holst; Victor A Gault; Peter R Flatt
GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.
American journal of physiology. Endocrinology and metabolism 2007;293(6):E1746-55.
2007: Nigel Irwin; K Hunter; Peter R Flatt
Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice.
Peptides 2007;28(11):2192-8.
2007: Nigel Irwin; Paula L McClean; Roslyn S Cassidy; Finbarr P M O'Harte; Brian D Green; Victor A Gault; Patrick Harriott; Peter R Flatt
Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.
Diabetes/metabolism research and reviews 2007;23(7):572-9.
2007: Liu Hui-Kang; Jane T McCluskey; Neville H McClenghan; Peter R Flatt
Streptozotocin-resistant BRIN-BD11 cells possess wide spectrum of toxin tolerance and enhanced insulin-secretory capacity.
Endocrine 2007;32(1):20-9.
2007: Victor A Gault; Paula L McClean; Roslyn S Cassidy; Nigel Irwin; Peter R Flatt
Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets.
Diabetologia 2007;50(8):1752-62.
2007: Nicola A Duffy; Brian D Green; Nigel Irwin; Victor A Gault; Aine M McKillop; Finbarr P M O'Harte; Peter R Flatt
Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
European journal of pharmacology 2007;568(1-3):278-86.
2007: Victor A Gault; Paula L McClean; Nigel Irwin; Gavin J Power; Jane T McCluskey; Peter R Flatt
Effects of subchronic treatment with the long-acting glucose-dependent insulinotropic polypeptide receptor agonist, N-AcGIP, on glucose homeostasis in streptozotocin-induced diabetes.
Pancreas 2007;35(1):73-9.
2007: Nigel Irwin; Paula L McClean; Finbarr P M O'Harte; Victor A Gault; Patrick Harriott; Peter R Flatt
Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.
Diabetologia 2007;50(7):1532-40.
2007: Peter R Flatt
Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 2007;4(2):151-3.
2007: Nigel Irwin; Paula L McClean; Peter R Flatt
Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Journal of peptide science : an official publication of the European Peptide Society 2007;13(6):400-5.
2007: Finbarr P M O'Harte; Kerry Hunter; Victor A Gault; Nigel Irwin; Brian D Green; Brett Greer; Patrick Harriott; Clifford J Bailey; Peter R Flatt
Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.
American journal of physiology. Endocrinology and metabolism 2007;292(6):E1674-82.
2007: Victor A Gault; Kerry Hunter; Nigel Irwin; Brian D Green; Brett Greer; Patrick Harriott; Finbarr P M O'Harte; Peter R Flatt
Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists.
Archives of biochemistry and biophysics 2007;461(2):263-74.
2007: Steven Patterson; Peter R Flatt; Neville H McClenaghan
Major metabolic homocysteine-derivative, homocysteine thiolactone, exerts changes in pancreatic beta-cell glucose-sensing, cellular signal transduction and integrity.
Archives of biochemistry and biophysics 2007;461(2):287-93.
2007: Brian D Green; Nigel Irwin; Peter R Flatt
Direct and indirect effects of obestatin peptides on food intake and the regulation of glucose homeostasis and insulin secretion in mice.
Peptides 2007;28(5):981-7.
2007: Steven Patterson; Siobhan M J Scullion; Jane T McCluskey; Peter R Flatt; Neville H McClenaghan
Prolonged exposure to homocysteine results in diminished but reversible pancreatic beta-cell responsiveness to insulinotropic agents.
Diabetes/metabolism research and reviews 2007;23(4):324-34.
2007: Nigel Irwin; Paula L McClean; Patrick Harriott; Peter R Flatt
Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice.
Experimental gerontology 2007;42(4):296-300.
2007: J M A Hannan; Liaquat Ali; Begum Rokeya; J Khaleque; M Akhter; Peter R Flatt; Yasser H A Abdel-Wahab
Soluble dietary fibre fraction of Trigonella foenum-graecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action.
The British journal of nutrition 2007;97(3):514-21.
2007: Jeremy C Parker; Nigel Irwin; Kerry S Lavery; Brian D Green; Finbarr P M O'Harte; Victor A Gault; Peter R Flatt
Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.
Biological chemistry 2007;388(2):221-6.
2007: Victor A Gault; Kerry Hunter; Nigel Irwin; Brett Greer; Brian D Green; Patrick Harriott; Finbarr P M O'Harte; Peter R Flatt
Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes.
Biological chemistry 2007;388(2):173-9.
2007: Yasser H A Abdel-Wahab; Lamin Marenah; Peter R Flatt; J Michael Conlon
Insulin releasing properties of the temporin family of antimicrobial peptides.
Protein and peptide letters 2007;14(7):702-7.
2007: J M A Hannan; Lamin Marenah; Liaquat Ali; Begum Rokeya; Peter R Flatt; Yasser H A Abdel-Wahab
Insulin secretory actions of extracts of Asparagus racemosus root in perfused pancreas, isolated islets and clonal pancreatic beta-cells.
The Journal of endocrinology 2007;192(1):159-68.
2007: Steven Patterson; Peter R Flatt; Neville H McClenaghan
Homocysteine-induced impairment of insulin secretion from clonal pancreatic BRIN-BD11 beta-cells is not prevented by catalase.
Pancreas 2007;34(1):144-51.
2006: Brian D Green; Peter R Flatt; Clifford J Bailey
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 2006;3(3):159-65.
2006: Peter R Flatt; Brian D Green
Nutrient regulation of pancreatic beta-cell function in diabetes: problems and potential solutions.
Biochemical Society transactions 2006;34(Pt 5):774-8.
2006: Brian D Green; Nigel Irwin; Nicola A Duffy; Victor A Gault; Finbarr P M O'Harte; Peter R Flatt
Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
European journal of pharmacology 2006;547(1-3):192-9.
2006: Jeremy C Parker; Kerry S Lavery; Nigel Irwin; Brian D Green; Brett Greer; Patrick Harriott; Finbarr P M O'Harte; Victor A Gault; Peter R Flatt
Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
The Journal of endocrinology 2006;191(1):93-100.
2006: Nigel Irwin; Gillian C Clarke; Brian D Green; Brett Greer; Patrick Harriott; Victor A Gault; Finbarr P M O'Harte; Peter R Flatt
Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
Biochemical pharmacology 2006;72(6):719-28.
2006: Neville H McClenaghan; Peter R Flatt; Andrew Ball
Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide.
The Journal of endocrinology 2006;190(3):889-96.
2006: J Michael Conlon; Steven Patterson; Peter R Flatt
Major contributions of comparative endocrinology to the development and exploitation of the incretin concept.
Journal of experimental zoology. Part A, Comparative experimental biology 2006;305(9):781-6.
2006: Brian D Green; Nigel Irwin; Roslyn S Cassidy; Victor A Gault; Peter R Flatt
Long-term administration of PACAP receptor antagonist, PACAP(6-27), impairs glucose tolerance and insulin sensitivity in obese diabetic ob/ob mice.
Peptides 2006;27(9):2343-9.
2006: Brian D Green; Kerry S Lavery; Nigel Irwin; Finbarr P M O'Harte; Patrick Harriott; Brett Greer; Clifford J Bailey; Peter R Flatt
Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
The Journal of pharmacology and experimental therapeutics 2006;318(2):914-21.
2006: Nigel Irwin; Brian D Green; Jeremy C Parker; Victor A Gault; Finbarr P M O'Harte; Peter R Flatt
Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16).
Regulatory peptides 2006;135(1-2):45-53.
2006: Lamin Marenah; Jane T McCluskey; Yasser H A Abdel-Wahab; Finbarr P M O'Harte; Neville H McClenaghan; Peter R Flatt
A stable analogue of glucose-dependent insulinotropic polypeptide, GIP(LysPAL16), enhances functional differentiation of mouse embryonic stem cells into cells expressing islet-specific genes and hormones.
Biological chemistry 2006;387(7):941-7.
2006: J M A Hannan; Liaquat Ali; J Khaleque; M Akhter; Peter R Flatt; Yasser H A Abdel-Wahab
Aqueous extracts of husks of Plantago ovata reduce hyperglycaemia in type 1 and type 2 diabetes by inhibition of intestinal glucose absorption.
The British journal of nutrition 2006;96(1):131-7.
2006: Steven Patterson; Peter R Flatt; Neville H McClenaghan
Homocysteine and other structurally-diverse amino thiols can alter pancreatic beta cell function without evoking cellular damage.
Biochimica et biophysica acta 2006;1760(7):1109-14.
2006: Brian D Green; Nigel Irwin; Peter R Flatt
Pituitary adenylate cyclase-activating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential.
Peptides 2006;27(6):1349-58.
2006: Ciaren Graham; Stephen C Richter; Stephen McClean; Edmund O'Kane; Peter R Flatt; Chris Shaw
Histamine-releasing and antimicrobial peptides from the skin secretions of the dusky gopher frog, Rana sevosa.
Peptides 2006;27(6):1313-9.
2006: Steven Patterson; Peter R Flatt; L Brennan; Philip Newsholme; Neville H McClenaghan
Detrimental actions of metabolic syndrome risk factor, homocysteine, on pancreatic beta-cell glucose metabolism and insulin secretion.
The Journal of endocrinology 2006;189(2):301-10.
2006: J M A Hannan; Lamin Marenah; Liaquat Ali; Begum Rokeya; Peter R Flatt; Yasser H A Abdel-Wahab
Ocimum sanctum leaf extracts stimulate insulin secretion from perfused pancreas, isolated islets and clonal pancreatic beta-cells.
The Journal of endocrinology 2006;189(1):127-36.
2006: Nigel Irwin; Brian D Green; Victor A Gault; Roslyn S Cassidy; Finbarr P M O'Harte; Patrick Harriott; Peter R Flatt
Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL37) in normal mice.
Peptides 2006;27(4):893-900.
2006: Jacqueline N Mathews; Peter R Flatt; Yasser H A Abdel-Wahab
Asparagus adscendens (Shweta musali) stimulates insulin secretion, insulin action and inhibits starch digestion.
The British journal of nutrition 2006;95(3):576-81.
2006: Nigel Irwin; Finbarr P M O'Harte; Victor A Gault; Brian D Green; Brett Greer; Patrick Harriott; Clifford J Bailey; Peter R Flatt
GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.
Journal of medicinal chemistry 2006;49(3):1047-54.
2006: Liu Hui-Kang; Brian D Green; Neville H McClenaghan; Jane T McCluskey; Peter R Flatt
Deleterious effects of supplementation with dehydroepiandrosterone sulphate or dexamethasone on rat insulin-secreting cells under in vitro culture condition.
Bioscience reports 2006;26(1):31-8.
2006: Aine M McKillop; John Lindsay; S Au; K I Mahood; Finbarr P M O'Harte; Peter R Flatt; Patrick M Bell
Meal-dependent regulation of circulating glycated insulin in type 2 diabetic subjects.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2006;38(2):94-7.
2006: Nigel Irwin; Brian D Green; Victor A Gault; Patrick Harriot; Finbarr P M O'Harte; Peter R Flatt
Stable agonist of glucose-dependent insulinotropic polypeptide (GIP) restores pancreatic beta cell glucose responsiveness but not glucose intolerance in aging mice.
Experimental gerontology 2006;41(2):151-6.
2006: Lamin Marenah; Peter R Flatt; David F Orr; Chris Shaw; Yasser H A Abdel-Wahab
Skin secretions of Rana saharica frogs reveal antimicrobial peptides esculentins-1 and -1B and brevinins-1E and -2EC with novel insulin releasing activity.
The Journal of endocrinology 2006;188(1):1-9.
2005: Lamin Marenah; Peter R Flatt; David F Orr; Chris Shaw; Yasser H A Abdel-Wahab
Isolation and structural characterization of novel Rugosin A-like insulinotropic peptide from the skin secretions of Rana saharica frog.
Peptides 2005;26(11):2117-23.
2005: Lamin Marenah; Peter R Flatt; David F Orr; Chris Shaw; Yasser H A Abdel-Wahab
Characterization of naturally occurring peptides in the skin secretion of Rana pipiens frog reveal pipinin-1 as the novel insulin-releasing agent.
The journal of peptide research : official journal of the American Peptide Society 2005;66(4):204-10.
2005: Brian D Green; Victor A Gault; Finbarr P M O'Harte; Peter R Flatt
A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Diabetes, obesity & metabolism 2005;7(5):595-604.
2005: Brian D Green; Liu Hui-Kang; Jane T McCluskey; Nicola A Duffy; Finbarr P M O'Harte; Neville H McClenaghan; Peter R Flatt
Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1.
Diabetes, obesity & metabolism 2005;7(5):563-9.
2005: Nigel Irwin; Brian D Green; mark mooney; Brett Greer; Patrick Harriott; Clifford J Bailey; Victor A Gault; Finbarr P M O'Harte; Peter R Flatt
A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.
The Journal of pharmacology and experimental therapeutics 2005;314(3):1187-94.
2005: Victor A Gault; Nigel Irwin; Brian D Green; Jane T McCluskey; Brett Greer; Clifford J Bailey; Patrick Harriott; Finbarr P M O'Harte; Peter R Flatt
Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes.
Diabetes 2005;54(8):2436-46.
2005: Nigel Irwin; Victor A Gault; Brian D Green; Brett Greer; Patrick Harriott; Clifford J Bailey; Peter R Flatt; Finbarr P M O'Harte
Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).
Biological chemistry 2005;386(7):679-87.
2005: Yasser H A Abdel-Wahab; Lamin Marenah; David F Orr; Chris Shaw; Peter R Flatt
Isolation and structural characterisation of a novel 13-amino acid insulin-releasing peptide from the skin secretion of Agalychnis calcarifer.
Biological chemistry 2005;386(6):581-7.
2005: Brian D Green; Nigel Irwin; Victor A Gault; Clifford J Bailey; Finbarr P M O'Harte; Peter R Flatt
Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.
The Journal of endocrinology 2005;185(2):307-17.
2005: John Lindsay; Nicola A Duffy; Aine M McKillop; J Ardill; Finbarr P M O'Harte; Peter R Flatt; Patrick M Bell
Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.
Diabetic medicine : a journal of the British Diabetic Association 2005;22(5):654-7.
2005: Ciaren Graham; Alexandra E Irvine; Stephen McClean; Stephen C Richter; Peter R Flatt; Chris Shaw
Peptide Tyrosine Arginine, a potent immunomodulatory peptide isolated and structurally characterized from the skin secretions of the dusky gopher frog, Rana sevosa.
Peptides 2005;26(5):737-43.
2005: Nigel Irwin; Brian D Green; Victor A Gault; Brett Greer; Patrick Harriott; Clifford J Bailey; Peter R Flatt; Finbarr P M O'Harte
Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.
Journal of medicinal chemistry 2005;48(4):1244-50.
2005: Andrew Ball; Peter R Flatt; Neville H McClenaghan
Alterations of insulin secretion following long-term manipulation of ATP-sensitive potassium channels by diazoxide and nateglinide.
Biochemical pharmacology 2005;69(1):59-63.
2004: Nigel Irwin; Victor A Gault; Brian D Green; Brett Greer; Jane T McCluskey; Patrick Harriott; Finbarr P M O'Harte; Peter R Flatt
Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice.
Biological chemistry 2004;385(9):845-52.
2004: Brian D Green; Victor A Gault; Peter R Flatt; Patrick Harriott; Brett Greer; Finbarr P M O'Harte
Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
Archives of biochemistry and biophysics 2004;428(2):136-43.
2004: Lamin Marenah; Chris Shaw; David F Orr; Stephen McClean; Peter R Flatt; Yasser H A Abdel-Wahab
Isolation and characterisation of an unexpected class of insulinotropic peptides in the skin of the frog Agalychnis litodryas.
Regulatory peptides 2004;120(1-3):33-8.
2004: Lamin Marenah; Stephen McClean; Peter R Flatt; David F Orr; Chris Shaw; Yasser H A Abdel-Wahab
Novel insulin-releasing peptides in the skin of Phyllomedusa trinitatis frog include 28 amino acid peptide from dermaseptin BIV precursor.
Pancreas 2004;29(2):110-5.
2004: João C Miguel; Steven Patterson; Yasser H A Abdel-Wahab; Paulo C F Mathias; Peter R Flatt
Time-correlation between membrane depolarization and intracellular calcium in insulin secreting BRIN-BD11 cells: studies using FLIPR.
Cell calcium 2004;36(1):43-50.
2004: Andrew Ball; Jane T McCluskey; Peter R Flatt; Neville H McClenaghan
Chronic exposure to tolbutamide and glibenclamide impairs insulin secretion but not transcription of K(ATP) channel components.
Pharmacological research : the official journal of the Italian Pharmacological Society 2004;50(1):41-6.
2004: Andrew Ball; Peter R Flatt; Neville H McClenaghan
Acute and long-term effects of nateglinide on insulin secretory pathways.
British journal of pharmacology 2004;142(2):367-73.
2004: Lamin Marenah; Peter R Flatt; David F Orr; Stephen McClean; Chris Shaw; Yasser H A Abdel-Wahab
Brevinin-1 and multiple insulin-releasing peptides in the skin of the frog Rana palustris.
The Journal of endocrinology 2004;181(2):347-54.
2004: Liu Hui-Kang; Brian D Green; Neville H McClenaghan; Jane T McCluskey; Peter R Flatt
Long-term beneficial effects of vanadate, tungstate, and molybdate on insulin secretion and function of cultured beta cells.
Pancreas 2004;28(4):364-8.
2004: Lamin Marenah; Peter R Flatt; David F Orr; Stephen McClean; Chris Shaw; Yasser H A Abdel-Wahab
Skin secretion of the toad Bombina variegata contains multiple insulin-releasing peptides including bombesin and entirely novel insulinotropic structures.
Biological chemistry 2004;385(3-4):315-21.
2004: Diane J Lees Murdock; Jacqueline Clarke; Peter R Flatt; Yvonne A Barnett; Christopher R Barnett
Role of CYP2E1 in ketone-stimulated insulin release in pancreatic B-cells.
Biochemical pharmacology 2004;67(5):875-84.
2004: Brian D Green; mark mooney; Victor A Gault; Nigel Irwin; Clifford J Bailey; Patrick Harriott; Brett Greer; Finbarr P M O'Harte; Peter R Flatt
N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.
The Journal of endocrinology 2004;180(3):379-88.
2004: Brian D Green; Victor A Gault; mark mooney; Nigel Irwin; Patrick Harriott; Brett Greer; Clifford J Bailey; Finbarr P M O'Harte; Peter R Flatt
Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Biological chemistry 2004;385(2):169-77.
2004: Liu Hui-Kang; Brian D Green; Peter R Flatt; Neville H McClenaghan; Jane T McCluskey
Effects of long-term exposure to nicotinamide and sodium butyrate on growth, viability, and the function of clonal insulin secreting cells.
Endocrine research 2004;30(1):61-8.
2004: Brian D Green; mark mooney; Victor A Gault; Nigel Irwin; Clifford J Bailey; Patrick Harriott; Brett Greer; Peter R Flatt; Finbarr P M O'Harte
Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).
Metabolism: clinical and experimental 2004;53(2):252-9.
2004: Brian D Green; Victor A Gault; Finbarr P M O'Harte; Peter R Flatt
Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
Current pharmaceutical design 2004;10(29):3651-62.
2004: Liu Hui-Kang; Brian D Green; Victor A Gault; Jane T McCluskey; Neville H McClenaghan; Finbarr P M O'Harte; Peter R Flatt
N-acetyl-GLP-1: a DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell-associated gene expression.
Cell biology international 2004;28(1):69-73.
2003: Brian D Green; Victor A Gault; Nigel Irwin; mark mooney; Clifford J Bailey; Patrick Harriott; Brett Greer; Peter R Flatt; Finbarr P M O'Harte
Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Biological chemistry 2003;384(12):1543-51.
2003: Brian D Green; Victor A Gault; mark mooney; Nigel Irwin; Clifford J Bailey; Patrick Harriott; Brett Greer; Peter R Flatt; Finbarr P M O'Harte
Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
Journal of molecular endocrinology 2003;31(3):529-40.
2003: Victor A Gault; Finbarr P M O'Harte; Peter R Flatt
Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?
Neuropeptides 2003;37(5):253-63.
2003: John Lindsay; Aine M McKillop; mark mooney; Finbarr P M O'Harte; Peter R Flatt; Patrick M Bell
Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes.
Diabetes research and clinical practice 2003;61(3):167-73.
2003: Victor A Gault; Peter R Flatt; Finbarr P M O'Harte
Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes.
Biochemical and biophysical research communications 2003;308(2):207-13.
2003: Victor A Gault; Finbarr P M O'Harte; Patrick Harriott; Peter R Flatt
Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo.
Metabolism: clinical and experimental 2003;52(6):679-87.
2003: Aine M McKillop; Angela Meade; Peter R Flatt; Finbarr P M O'Harte
Evaluation of the site(s) of glycation in human proinsulin by ion-trap LCQ electrospray ionization mass spectrometry.
Regulatory peptides 2003;113(1-3):1-8.
2003: John Lindsay; Aine M McKillop; mark mooney; Peter R Flatt; Patrick M Bell; Finbarr P M O'Harte
Meal-induced 24-hour profile of circulating glycated insulin in type 2 diabetic subjects measured by a novel radioimmunoassay.
Metabolism: clinical and experimental 2003;52(5):631-5.
2003: John Lindsay; Aine M McKillop; mark mooney; Finbarr P M O'Harte; Patrick M Bell; Peter R Flatt
Demonstration of increased concentrations of circulating glycated insulin in human Type 2 diabetes using a novel and specific radioimmunoassay.
Diabetologia 2003;46(4):475-8.
2003: Victor A Gault; Finbarr P M O'Harte; Patrick Harriott; mark mooney; Brian D Green; Peter R Flatt
Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Diabetologia 2003;46(2):222-30.
2003: Steven J Hunter; Alison C Boyd; Finbarr P M O'Harte; Aine M McKillop; M Ivan Wiggam; mark mooney; Jane T McCluskey; John Lindsay; Cieran N Ennis; Raymond Gamble; Brian Sheridan; Christopher R Barnett; Helene McNulty; Patrick M Bell; Peter R Flatt
Demonstration of glycated insulin in human diabetic plasma and decreased biological activity assessed by euglycemic-hyperinsulinemic clamp technique in humans.
Diabetes 2003;52(2):492-8.
2003: João C Miguel; Yasser H A Abdel-Wahab; Brian D Green; Paulo C F Mathias; Peter R Flatt
Cooperative enhancement of insulinotropic action of GLP-1 by acetylcholine uncovers paradoxical inhibitory effect of beta cell muscarinic receptor activation on adenylate cyclase activity.
Biochemical pharmacology 2003;65(2):283-92.
2003: Victor A Gault; Nigel Irwin; Patrick Harriott; Peter R Flatt; Finbarr P M O'Harte
DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP.
Cell biology international 2003;27(1):41-6.
2003: Victor A Gault; Peter R Flatt; Patrick Harriott; mark mooney; Clifford J Bailey; Finbarr P M O'Harte
Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide.
The Journal of endocrinology 2003;176(1):133-41.
2002: S F Picton; Jane T McCluskey; Peter R Flatt; Neville H McClenaghan
Effects of cytotoxic agents on functional integrity and antioxidant enzymes in clonal beta-cells.
Diabetes & metabolism 2002;28(6 Pt 2):3S70-7; discussion 3S108-12.
2002: Aine M McKillop; Yasser H A Abdel-Wahab; mark mooney; Finbarr P M O'Harte; Peter R Flatt
Secretion of glycated insulin from pancreatic beta-cells in diabetes represents a novel aspect of beta-cell dysfunction and glucose toxicity.
Diabetes & metabolism 2002;28(6 Pt 2):3S61-9; discussion 3S108-12.
2002: Victor A Gault; Jeremy C Parker; Patrick Harriott; Peter R Flatt; Finbarr P M O'Harte
Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo.
The Journal of endocrinology 2002;175(2):525-33.
2002: Victor A Gault; Peter R Flatt; Clifford J Bailey; Patrick Harriott; Brett Greer; mark mooney; Finbarr P M O'Harte
Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.
The Biochemical journal 2002;367(Pt 3):913-20.
2002: Victor A Gault; Patrick Harriott; Peter R Flatt; Finbarr P M O'Harte
Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide.
Bioscience reports 2002;22(5-6):523-8.
2002: Finbarr P M O'Harte; Victor A Gault; Jeremy C Parker; Patrick Harriott; mark mooney; Clifford J Bailey; Peter R Flatt
Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.
Diabetologia 2002;45(9):1281-91.
2002: Yasser H A Abdel-Wahab; Finbarr P M O'Harte; mark mooney; Christopher R Barnett; Peter R Flatt
Vitamin C supplementation decreases insulin glycation and improves glucose homeostasis in obese hyperglycemic (ob/ob) mice.
Metabolism: clinical and experimental 2002;51(4):514-7.
2002: Victor A Gault; Finbarr P M O'Harte; Patrick Harriott; Peter R Flatt
Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide.
Biochemical and biophysical research communications 2002;290(5):1420-6.
2002: M Hamid; Jane T McCluskey; Neville H McClenaghan; Peter R Flatt
Comparison of the secretory properties of four insulin-secreting cell lines.
Endocrine research 2002;28(1-2):35-47.
2002: mark mooney; Yasser H A Abdel-Wahab; Aine M McKillop; Finbarr P M O'Harte; Peter R Flatt
Evaluation of glycated glucagon-like peptide-1(7-36)amide in intestinal tissue of normal and diabetic animal models.
Biochimica et biophysica acta 2002;1569(1-3):75-80.
2002: João C Miguel; Yasser H A Abdel-Wahab; Paulo C F Mathias; Peter R Flatt
Muscarinic receptor subtypes mediate stimulatory and paradoxical inhibitory effects on an insulin-secreting beta cell line.
Biochimica et biophysica acta 2002;1569(1-3):45-50.
2001: mark mooney; Yasser H A Abdel-Wahab; L M Morgan; Finbarr P M O'Harte; Peter R Flatt
Detection of glycated gastric inhibitory polypeptide within the intestines of diabetic obese (ob/ob) mice.
Endocrine 2001;16(3):167-71.
2001: Aine M McKillop; mark mooney; Patrick Harriott; Peter R Flatt; Finbarr P M O'Harte
Evaluation of glycated insulin in diabetic animals using immunocytochemistry and radioimmunoassay.
Biochemical and biophysical research communications 2001;286(3):524-8.
2001: M Hamid; Jane T McCluskey; Neville H McClenaghan; Peter R Flatt
Comparative functional study of clonal insulin-secreting cells cultured in five commercially available tissue culture media.
Cell transplantation 2001;10(2):153-9.
2001: Neville H McClenaghan; Andrew Ball; Peter R Flatt
Specific desensitization of sulfonylurea- but not imidazoline-induced insulin release after prolonged tolbutamide exposure.
Biochemical pharmacology 2001;61(5):527-36.
2001: Finbarr P M O'Harte; mark mooney; CM Kelly; Aine M McKillop; Peter R Flatt
Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
Regulatory peptides 2001;96(3):95-104.
2001: S F Picton; Peter R Flatt; Neville H McClenaghan
Differential acute and long term actions of succinic acid monomethyl ester exposure on insulin-secreting BRIN-BD11 cells.
International journal of experimental diabetes research 2001;2(1):19-27.
2001: M Hamid; Jane T McCluskey; Neville H McClenaghan; Peter R Flatt
Functional examination of microencapsulated bioengineered insulin-secreting beta-cells.
Cell biology international 2001;25(6):553-6.
2000: Andrew Ball; Peter R Flatt; Neville H McClenaghan
Stimulation of insulin secretion in clonal BRIN-BD11 cells by the imidazoline derivatives KU14r and RX801080.
Pharmacological research : the official journal of the Italian Pharmacological Society 2000;42(6):575-9.
2000: Andrew Ball; Peter R Flatt; Neville H McClenaghan
Desensitization of sulphonylurea- and nutrient-induced insulin secretion following prolonged treatment with glibenclamide.
European journal of pharmacology 2000;408(3):327-33.
2000: Finbarr P M O'Harte; Alison C Boyd; Aine M McKillop; Yasser H A Abdel-Wahab; Helene McNulty; Christopher R Barnett; J M Conlon; P Højrup; Peter R Flatt
Structure, antihyperglycemic activity and cellular actions of a novel diglycated human insulin.
Peptides 2000;21(10):1519-26.
2000: Aine M McKillop; J T McCluskey; Alison C Boyd; mark mooney; Peter R Flatt; Finbarr P M O'Harte
Production and characterization of specific antibodies for evaluation of glycated insulin in plasma and biological tissues.
The Journal of endocrinology 2000;167(1):153-63.
2000: Alison C Boyd; Yasser H A Abdel-Wahab; Aine M McKillop; Helene McNulty; Christopher R Barnett; Finbarr P M O'Harte; Peter R Flatt
Impaired ability of glycated insulin to regulate plasma glucose and stimulate glucose transport and metabolism in mouse abdominal muscle.
Biochimica et biophysica acta 2000;1523(1):128-34.
2000: M Hamid; Jane T McCluskey; Neville H McClenaghan; Peter R Flatt
Culture and function of electrofusion-derived clonal insulin-secreting cells immobilized on solid and macroporous microcarrier beads.
Bioscience reports 2000;20(3):167-76.
2000: Finbarr P M O'Harte; mark mooney; CM Kelly; Peter R Flatt
Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide.
The Journal of endocrinology 2000;165(3):639-48.
2000: Neville H McClenaghan; Andrew Ball; Peter R Flatt
Induced desensitization of the insulinotropic effects of antidiabetic drugs, BTS 67 582 and tolbutamide.
British journal of pharmacology 2000;130(2):478-84.
2000: Andrew Ball; Jane T McCluskey; Peter R Flatt; Neville H McClenaghan
Drug-induced desensitization of insulinotropic actions of sulfonylureas.
Biochemical and biophysical research communications 2000;271(1):234-9.
2000: Finbarr P M O'Harte; mark mooney; A Lawlor; Peter R Flatt
N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo.
Biochimica et biophysica acta 2000;1474(1):13-22.
2000: Neville H McClenaghan; Peter R Flatt
Metabolic and K(ATP) channel-independent actions of keto acid initiators of insulin secretion.
Pancreas 2000;20(1):38-46.
2000: AM Gray; Yasser H A Abdel-Wahab; Peter R Flatt
The traditional plant treatment, Sambucus nigra (elder), exhibits insulin-like and insulin-releasing actions in vitro.
The Journal of nutrition 2000;130(1):15-20.
1999: Yasser H A Abdel-Wahab; Finbarr P M O'Harte; mark mooney; J M Conlon; Peter R Flatt
N-terminal glycation of cholecystokinin-8 abolishes its insulinotropic action on clonal pancreatic B-cells.
Biochimica et biophysica acta 1999;1452(1):60-7.
1999: Neville H McClenaghan; Peter R Flatt
Physiological and pharmacological regulation of insulin release: insights offered through exploitation of insulin-secreting cell lines.
Diabetes, obesity & metabolism 1999;1(3):137-50.
1999: Finbarr P M O'Harte; mark mooney; Peter R Flatt
NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity.
Diabetes 1999;48(4):758-65.
1999: AM Gray; Peter R Flatt
Insulin-releasing and insulin-like activity of the traditional anti-diabetic plant Coriandrum sativum (coriander).
The British journal of nutrition 1999;81(3):203-9.
1999: AM Gray; Peter R Flatt
Insulin-secreting activity of the traditional antidiabetic plant Viscum album (mistletoe).
The Journal of endocrinology 1999;160(3):409-14.
1999: Neville H McClenaghan; Peter R Flatt
Glucose and non-glucidic nutrients exert permissive effects on 2-keto acid regulation of pancreatic beta-cell function.
Biochimica et biophysica acta 1999;1426(1):110-8.
1999: Neville H McClenaghan; Peter R Flatt
Engineering cultured insulin-secreting pancreatic B-cell lines.
Journal of molecular medicine (Berlin, Germany) 1999;77(1):235-43.
1998: AM Gray; Peter R Flatt
Antihyperglycemic actions of Eucalyptus globulus (Eucalyptus) are associated with pancreatic and extra-pancreatic effects in mice.
The Journal of nutrition 1998;128(12):2319-23.
1998: Finbarr P M O'Harte; Yasser H A Abdel-Wahab; J M Conlon; Peter R Flatt
Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells.
Biochimica et biophysica acta 1998;1425(2):319-27.
1998: Finbarr P M O'Harte; Yasser H A Abdel-Wahab; J M Conlon; Peter R Flatt
Glycation of glucagon-like peptide-1(7-36)amide: characterization and impaired action on rat insulin secreting cells.
Diabetologia 1998;41(10):1187-93.
1998: Finbarr P M O'Harte; mark mooney; CM Kelly; Peter R Flatt
Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation.
Diabetes 1998;47(10):1619-24.
1998: Neville H McClenaghan; Christopher R Barnett; Peter R Flatt
Na+ cotransport by metabolizable and nonmetabolizable amino acids stimulates a glucose-regulated insulin-secretory response.
Biochemical and biophysical research communications 1998;249(2):299-303.
1998: AM Gray; Peter R Flatt
Actions of the traditional anti-diabetic plant, Agrimony eupatoria (agrimony): effects on hyperglycaemia, cellular glucose metabolism and insulin secretion.
The British journal of nutrition 1998;80(1):109-14.
1998: AM Gray; Peter R Flatt
Insulin-releasing and insulin-like activity of Agaricus campestris (mushroom).
The Journal of endocrinology 1998;157(2):259-66.
1998: Finbarr P M O'Harte; Yasser H A Abdel-Wahab; J M Conlon; Peter R Flatt
Glycated IAPP shows a reduced inhibitory action on insulin secretion.
Biochemical Society transactions 1998;26(1):S6.
1998: Finbarr P M O'Harte; AM Gray; Peter R Flatt
Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle.
The Journal of endocrinology 1998;156(2):237-43.
1998: Neville H McClenaghan; Peter R Flatt; C J Bailey
Insulin-releasing action of the novel antidiabetic agent BTS 67 582.
British journal of pharmacology 1998;123(3):400-4.
1997: Yasser H A Abdel-Wahab; Finbarr P M O'Harte; Alison C Boyd; Christopher R Barnett; Peter R Flatt
Glycation of insulin results in reduced biological activity in mice.
Acta diabetologica 1997;34(4):265-70.
1997: AM Gray; Peter R Flatt
Pancreatic and extra-pancreatic effects of the traditional anti-diabetic plant, Medicago sativa (lucerne).
The British journal of nutrition 1997;78(2):325-34.
1997: J Clarke; Peter R Flatt; Christopher R Barnett
Cytochrome P450 1A-like proteins expressed in the islets of Langerhans and altered pancreatic beta-cell secretory responsiveness.
British journal of pharmacology 1997;121(3):389-94.
1997: AM Gray; Peter R Flatt
Nature's own pharmacy: the diabetes perspective.
The Proceedings of the Nutrition Society 1997;56(1B):507-17.
1997: Peter R Flatt; Yasser H A Abdel-Wahab; Alison C Boyd; Christopher R Barnett; Finbarr P M O'Harte
Pancreatic B-cell dysfunction and glucose toxicity in non-insulin-dependent diabetes.
The Proceedings of the Nutrition Society 1997;56(1B):243-62.
1997: Finbarr P M O'Harte; A C Penney; Peter R Flatt
Glycation of insulin by phosphorylated and nonphosphorylated reducing sugars.
Biochemical Society transactions 1997;25(1):150S.
1997: M McDonagh; Liaquat Ali; A Kahn; Peter R Flatt; Yvonne A Barnett; Christopher R Barnett
Antioxidant status, oxidative stress and DNA damage in the aetiology of malnutrition related diabetes mellitus.
Biochemical Society transactions 1997;25(1):146S.
1997: Neville H McClenaghan; Christopher R Barnett; Peter R Flatt
Mechanisms of action of cationic amino acids on insulin-secreting BRIN-BD11 cells.
Biochemical Society transactions 1997;25(1):144S.
1997: J Clarke; James Coulter; Peter R Flatt; Christopher R Barnett
Islet antioxidant and second phase enzyme levels following CYP1A, CYP2E, CYP2B and CYP4A induction.
Biochemical Society transactions 1997;25(1):133S.
1997: Yasser H A Abdel-Wahab; Finbarr P M O'Harte; Christopher R Barnett; Peter R Flatt
Glycation of insulin in a cultured insulin-secreting cell line.
Biochemical Society transactions 1997;25(1):128S.
1997: J C Clarke; Peter R Flatt; Christopher R Barnett
The role of cytochrome P450 in altered pancreatic B-cell responsiveness.
Biochemical Society transactions 1997;25(1):122S.
1997: A M Wilson; Christopher R Barnett; Peter R Flatt
Altered secretory responsiveness of BRIN-BD11 cells cultured under hyperglycaemic conditions is not readily reversed by subsequent culture in lower glucose concentrations.
Advances in experimental medicine and biology 1997;426():379-84.
1997: Finbarr P M O'Harte; AM Gray; Yasser H A Abdel-Wahab; Peter R Flatt
Effects of non-glycated and glycated glucagon-like peptide-1(7-36) amide on glucose metabolism in isolated mouse abdominal muscle.
Peptides 1997;18(9):1327-33.
1997: Yasser H A Abdel-Wahab; Finbarr P M O'Harte; Christopher R Barnett; Peter R Flatt
Characterization of insulin glycation in insulin-secreting cells maintained in tissue culture.
The Journal of endocrinology 1997;152(1):59-67.
1996: J Clarke; J Snelling; C Ioannides; Peter R Flatt; Christopher R Barnett
Effect of vitamin C supplementation on hepatic cytochrome P450 mixed-function oxidase activity in streptozotocin-diabetic rats.
Toxicology letters 1996;89(3):249-56.
1996: Neville H McClenaghan; Christopher R Barnett; Finbarr P M O'Harte; Peter R Flatt
Mechanisms of amino acid-induced insulin secretion from the glucose-responsive BRIN-BD11 pancreatic B-cell line.
The Journal of endocrinology 1996;151(3):349-57.
1996: Yasser H A Abdel-Wahab; Finbarr P M O'Harte; H Ratcliff; Neville H McClenaghan; Christopher R Barnett; Peter R Flatt
Glycation of insulin in the islets of Langerhans of normal and diabetic animals.
Diabetes 1996;45(11):1489-96.
1996: Neville H McClenaghan; Christopher R Barnett; E Ah-Sing; Yasser H A Abdel-Wahab; Finbarr P M O'Harte; T W Yoon; S K Swanston-Flatt; Peter R Flatt
Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion.
Diabetes 1996;45(8):1132-40.
1996: Neville H McClenaghan; AM Gray; Christopher R Barnett; Peter R Flatt
Hexose recognition by insulin-secreting BRIN-BD11 cells.
Biochemical and biophysical research communications 1996;223(3):724-8.
1996: Peter R Flatt
Pancreatic B-cells as mediators of metabolic effects of regulatory peptides.
Biochemical Society transactions 1996;24(2):570-5.
1996: Neville H McClenaghan; Christopher R Barnett; Finbarr P M O'Harte; S K Swanston-Flatt; E Ah-Sing; Peter R Flatt
Characteristics of BRIN-BG5 and BRIN-BG7, two novel glucose-responsive insulin-secreting cell lines produced by electrofusion.
The Journal of endocrinology 1996;148(3):409-17.
1996: Neville H McClenaghan; Christopher R Barnett; E Ah-Sing; S K Swanston-Flatt; Peter R Flatt
Secretory properties of clonal insulin-secreting BRIN-BG5 cells, produced by electrofusion.
Biochemical Society transactions 1996;24(1):101S.
1996: Finbarr P M O'Harte; P Højrup; Christopher R Barnett; Peter R Flatt
Identification of the site of glycation of human insulin.
Peptides 1996;17(8):1323-30.
1995: A Irizar; C R Barnett; Peter R Flatt; Costas Ioannides
Defective expression of cytochrome P450 proteins in the liver of the genetically obese Zucker rat.
European journal of pharmacology 1995;293(4):385-93.
1994: Finbarr P M O'Harte; Alison C Boyd; Yasser H A Abdel-Wahab; Christopher R Barnett; Peter R Flatt
Characterization of the glycation of human insulin by reversed-phase HPLC.
Biochemical Society transactions 1994;22(2):239S.
1994: Yasser H A Abdel-Wahab; Finbarr P M O'Harte; Christopher R Barnett; Peter R Flatt
Studies of the effect of glycation of insulin on glucose metabolism in isolated mouse diaphragm muscle.
Biochemical Society transactions 1994;22(2):238S.
1994: Neville H McClenaghan; T W Yoon; Christopher R Barnett; A M Wilson; Yasser H A Abdel-Wahab; S Swanston-Flatt; E Ah-Singh; Peter R Flatt
Effect of glucose and amino acids on insulin-secretion from a novel pancreatic B-cell line produced by electrofusion.
Biochemical Society transactions 1994;22(2):237S.
1994: C R Barnett; Peter R Flatt; Costas Ioannides
Modulation of the rat hepatic cytochrome P450 composition by long-term streptozotocin-induced insulin-dependent diabetes.
Journal of biochemical toxicology 1994;9(2):63-9.
1994: Peter R Flatt; O Shibier; J Szecowka; Per-Olof Berggren
New perspectives on the actions of sulphonylureas and hyperglycaemic sulphonamides on the pancreatic beta-cell.
Diabète & métabolisme 1994;20(2):157-62.
1994: Peter R Flatt; Christopher R Barnett; S K Swanston-Flatt
Mechanisms of pancreatic B-cell dysfunction and glucose toxicity in non-insulin-dependent diabetes.
Biochemical Society transactions 1994;22(1):18-23.
1994: B M McDermott; Peter R Flatt; John J Strain
Effects of copper deficiency and experimental diabetes on tissue antioxidant enzyme levels in rats.
Annals of nutrition & metabolism 1994;38(5):263-9.
1993: C R Barnett; S Rudd; Peter R Flatt; Costas Ioannides
Sex differences in the diabetes-induced modulation of rat hepatic cytochrome P450 proteins.
Biochemical pharmacology 1993;45(2):313-9.
1992: C R Barnett; L Petrides; J Wilson; Peter R Flatt; Costas Ioannides
Induction of rat hepatic mixed-function oxidases by acetone and other physiological ketones: their role in diabetes-induced changes in cytochrome P450 proteins.
Xenobiotica; the fate of foreign compounds in biological systems 1992;22(12):1441-50.
1992: C R Barnett; R A Abbott; C J Bailey; Peter R Flatt; Costas Ioannides
Cytochrome P-450-dependent mixed-function oxidase and glutathione S-transferase activities in spontaneous obesity-diabetes.
Biochemical pharmacology 1992;43(8):1868-71.
1992: C R Barnett; J Wilson; C R Wolf; Peter R Flatt; Costas Ioannides
Hyperinsulinaemia causes a preferential increase in hepatic P4501A2 activity.
Biochemical pharmacology 1992;43(6):1255-61.
1991: S K Swanston-Flatt; Peter R Flatt; C Day; C J Bailey
Traditional dietary adjuncts for the treatment of diabetes mellitus.
The Proceedings of the Nutrition Society 1991;50(3):641-51.
1991: Peter R Flatt; Christopher R Barnett; O Shibier; S K Swanston-Flatt
Direct and indirect actions of nutrients in the regulation of insulin secretion from the pancreatic beta cells.
The Proceedings of the Nutrition Society 1991;50(3):559-66.
1991: Peter R Flatt; C J Bailey; J Michael Conlon
Somatostatin, gastrin-releasing peptide and gastrin in the stomach of rats with streptozotocin-induced diabetes and insulinoma.
The Journal of nutrition 1991;121(9):1414-7.
1991: Peter R Flatt; P Kwasowski; R J Howland; C J Bailey
Gastric inhibitory polypeptide and insulin responses to orally administered amino acids in genetically obese hyperglycemic (ob/ob) mice.
The Journal of nutrition 1991;121(7):1123-8.
1990: S K Swanston-Flatt; C Day; C J Bailey; Peter R Flatt
Traditional plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice.
Diabetologia 1990;33(8):462-4.
1990: C R Barnett; Peter R Flatt; Costas Ioannides
Induction of hepatic microsomal P450 I and IIB proteins by hyperketonaemia.
Biochemical pharmacology 1990;40(2):393-7.
1990: C R Barnett; G G Gibson; C R Wolf; Peter R Flatt; Costas Ioannides
Induction of cytochrome P450III and P450IV family proteins in streptozotocin-induced diabetes.
The Biochemical journal 1990;268(3):765-9.
1990: Costas Ioannides; Andrew Ayrton; A Keele; David F V Lewis; Peter R Flatt; R Walker
Mechanism of the in vitro antimutagenic action of retinol.
Mutagenesis 1990;5(3):257-62.
1990: Peter R Flatt
Defective regulation of insulin secretion in diabetes and insulinoma.
Biochemical Society transactions 1990;18(1):124-7.
1990: Peter R Flatt; O Shiber; S M Hampton; V Marks
Stimulatory effects of glucagon-like peptides on human insulinoma cells and insulin-releasing clonal RINm5F cells.
Diabetes research (Edinburgh, Scotland) 1990;13(2):55-9.
1990: C R Barnett; Peter R Flatt; Costas Ioannides
Hyperketonaemia markedly modulates the metabolic activation of chemical carcinogens.
Chemico-biological interactions 1990;74(3):281-9.
1990: Peter R Flatt; C J Bailey; P Kwasowski; S K Swanston-Flatt
Effects of diets rich in sucrose, coconut fat and safflowerseed oil on the development of the obese hyperglycaemic (ob/ob) syndrome in mice.
Diabetes research (Edinburgh, Scotland) 1990;13(1):23-8.
1989: Peter R Flatt; P Kwasowski; C J Bailey
Stimulation of gastric inhibitory polypeptide release in ob/ob mice by oral administration of sugars and their analogues.
The Journal of nutrition 1989;119(9):1300-3.
1989: Peter R Flatt; O Shibier; Costas Ioannides; S K Swanston-Flatt
Studies on the chemical and immunological destruction of insulin-secreting islet cell tumours.
Experimental and clinical endocrinology 1989;93(2-3):193-202.
1989: Peter R Flatt; L Juntti-Berggren; Per-Olof Berggren; BJ Gould; S K Swanston-Flatt
Failure of glucose tolerance factor-containing Brewer's yeast to ameliorate spontaneous diabetes in C57BL/KsJ DB/DB mice.
Diabetes research (Edinburgh, Scotland) 1989;10(3):147-51.
1989: Peter R Flatt; L Juntti-Berggren; Per-Olof Berggren; BJ Gould; S K Swanston-Flatt
Effects of dietary inorganic trivalent chromium (Cr3+) on the development of glucose homeostasis in rats.
Diabète & métabolisme 1989;15(2):93-7.
1989: S K Swanston-Flatt; C Day; Peter R Flatt; BJ Gould; C J Bailey
Glycaemic effects of traditional European plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice.
Diabetes research (Edinburgh, Scotland) 1989;10(2):69-73.
1989: Peter R Flatt; S L Bass; Andrew Ayrton; J Trinick; Costas Ioannides
Metabolic activation of chemical carcinogens by hepatic preparations from streptozotocin-treated rats.
Diabetologia 1989;32(2):135-9.
1989: S K Swanston-Flatt; C Day; C J Bailey; Peter R Flatt
Evaluation of traditional plant treatments for diabetes: studies in streptozotocin diabetic mice.
Acta diabetologica latina 1989;26(1):51-5.
1988: C R Barnett; Peter R Flatt; Costas Ioannides
Role of ketone bodies in the diabetes-induced changes in hepatic mixed-function oxidase activities.
Biochimica et biophysica acta 1988;967(2):250-4.
1988: Peter R Flatt; M G DeSilva; S K Swanston-Flatt; CJ Powell; Vincent Marks
Tumour formation and insulin secretion by clonal RINm5F cells following repeated subcutaneous transplantation in NEDH rats.
The Journal of endocrinology 1988;118(3):429-37.
1988: Peter R Flatt; H Abrahamsson; P Arkhammar; Per-Olof Berggren; P Rorsman; S K Swanston-Flatt
Measurements of membrane potential, transmembrane 45Ca fluxes, cytoplasmic free Ca2+ concentration and insulin release by transplantable rat insulinoma cells maintained in tissue culture.
British journal of cancer 1988;58(1):22-9.
1988: Costas Ioannides; S L Bass; Andrew Ayrton; J Trinick; R Walker; Peter R Flatt
Streptozotocin-induced diabetes modulates the metabolic activation of chemical carcinogens.
Chemico-biological interactions 1988;68(3-4):189-202.
1988: S K Swanston-Flatt; Peter R Flatt
Effects of cationic modification on 45Ca uptake and insulin release by transplantable rat insulinoma cells maintained in tissue culture.
General pharmacology 1988;19(3):471-4.
1988: S K Swanston-Flatt; Peter R Flatt
Effects of amino acids, hormones and drugs on insulin release and 45Ca uptake by transplantable rat insulinoma cells maintained in tissue culture.
General pharmacology 1988;19(2):239-42.
1987: Peter R Flatt; M DeSilva; S K Swanston-Flatt; Vincent Marks
Insulin secretion in vivo and in vitro from transplantable NEDH rat insulinoma and derived clonal RINm5F cell line.
Diabetes research (Edinburgh, Scotland) 1987;6(2):85-90.
1987: Peter R Flatt; S K Swanston-Flatt; CJ Powell; Vincent Marks
Defective regulation of insulin release and transmembrane Ca2+ fluxes by human islet cell tumours.
British journal of cancer 1987;56(4):459-64.
1987: Peter R Flatt; S K Swanston-Flatt; K Snell; K S Tan; Vincent Marks
Effects of diet-induced ketosis in rats with hypoglycaemia due to a serially transplantable insulinoma.
Diabète & métabolisme 1987;13(5):503-7.
1987: Peter R Flatt; C J Bailey; S K Swanston-Flatt; K S Tan; Vincent Marks
Reversal of diabetes by syngeneic transplantation of a radiation-induced rat insulinoma.
Diabetes research and clinical practice 1987;3(2):63-9.
1987: Peter R Flatt; K S Tan; S K Swanston-Flatt; C J Bailey; Vincent Marks
Defective diurnal changes of food intake, plasma glucose and insulin in rats with a transplantable islet cell tumour.
Hormone research 1987;27(1):47-52.
1987: Peter R Flatt; S K Swanston-Flatt; K S Tan; Vincent Marks
Effects of cytotoxic drugs and inhibitors of insulin secretion on a serially transplantable rat insulinoma and cultured rat insulinoma cells.
General pharmacology 1987;18(3):293-7.
1987: Peter R Flatt; K S Tan; S K Swanston-Flatt; J D Webster; Vincent Marks
Metabolic effects and secretory properties of a radiation-induced transplantable rat insulinoma.
Comparative biochemistry and physiology. A, Comparative physiology 1987;87(1):175-81.
1986: BJ Gould; Peter R Flatt; S Kotecha; S Collett; S K Swanston-Flatt
Measurement of glycosylated haemoglobins and glycosylated plasma proteins in animal models with diabetes or inappropriate hypoglycaemia.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1986;18(12):795-9.
1986: Peter R Flatt; K S Tan; C J Bailey; CJ Powell; S K Swanston-Flatt; Vincent Marks
Effects of transplantation and resection of a radiation-induced rat insulinoma on glucose homeostasis and the endocrine pancreas.
British journal of cancer 1986;54(4):685-92.
1983: Peter R Flatt; C J Bailey; P Kwasowski; S K Swanston-Flatt; V Marks
Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice.
Diabetes 1983;32(5):433-5.